There are no official guidelines to assist in answering this question. I will search for relevant research papers instead.
The FDA Drug Labels for phenelzine (PO) do not address this question.
From the Research
Relationship between Phenelzine and Parkinson's-like symptoms
- Phenelzine, a monoamine oxidase inhibitor (MAOI), has been associated with the development of Parkinson's-like symptoms in some cases 1.
- A study published in 1986 reported a case of a 42-year-old woman who developed a parkinsonian syndrome 5 weeks after administration of phenelzine, which resolved after discontinuation of the drug 1.
- Another study published in 2011 discussed the use of MAOIs, including phenelzine, in the treatment of Parkinson's disease, highlighting their potential benefits and limitations 2.
- The same study noted that selective, reversible MAO-A inhibitors are recommended for the treatment of depression in Parkinson's disease, while selective, irreversible MAO-B inhibitors like selegiline and rasagiline are recommended for the treatment of akinesia and motor fluctuations 2.
Mechanisms and Interactions
- Phenelzine has been shown to have inhibitory effects on amine oxidases, aminotransferases, and decarboxylases, and may lower pyridoxal phosphate levels 3.
- The drug has also been reported to cause pyridoxal deficiency, weight gain, sedation, and sexual dysfunction, although rare cases of hepatic damage and failure, or neurotoxicity have been noted 3.
- A 2022 review of the neuroprotective effects of phenelzine highlighted its potential benefits in animal models of stroke, spinal cord injury, traumatic brain injury, and multiple sclerosis, as well as its effects on the GABA-glutamate balance in brain and sequestration of reactive aldehydes 4.
Clinical Implications
- The use of phenelzine and other MAOIs in the treatment of depression and Parkinson's disease requires careful consideration of their potential benefits and risks 5, 2, 3.
- Further research is needed to fully understand the relationship between phenelzine and Parkinson's-like symptoms, as well as the drug's potential neuroprotective effects 1, 4.